Results 21 to 30 of about 51,741 (305)

Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine through 6 Months

New England Journal of Medicine, 2021
Background BNT162b2 is a lipid nanoparticle–formulated, nucleoside-modified RNA vaccine encoding a prefusion-stabilized, membrane-anchored severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) full-length spike protein.
Stephen J. Thomas, E. Moreira, N. Kitchin, J. Absalon, A. Gurtman, S. Lockhart, John L. Perez, Gonzalo Pérez Marc, F. Polack, C. Zerbini, R. Bailey, K. Swanson, Xia Xu, Satrajit Roychoudhury, K. Koury, S. Bouguermouh, W. Kalina, David Cooper, R. Frenck, L. Hammitt, Ö. Türeci, H. Nell, A. Schaefer, S. Ünal, Qi Yang, P. Liberator, D. Tresnan, Susan H. Mather, P. Dormitzer, U. Şahin, W. Gruber, K. Jansen   +31 more
semanticscholar   +1 more source

Longitudinal Analysis of SARS-CoV-2-Specific Cellular and Humoral Immune Responses and Breakthrough Infection following BNT162b2/BNT162b2/BNT162b2 and ChAdOx1/ChAdOx1/BNT162b2 Vaccination: A Prospective Cohort in Naive Healthcare Workers

Vaccines, 2023
Assessing immune responses post-SARS-CoV-2 vaccination is crucial for optimizing vaccine strategies. This prospective study aims to evaluate immune responses and breakthrough infection in 235 infection-naïve healthcare workers up to 13–15 months after initial vaccination in two vaccine groups (108 BNT/BNT/BNT and 127 ChAd/ChAd/BNT).
Geon Young Ko, Jihyun Lee, Hyunjoo Bae, Ji Hyeong Ryu, Hye-Sun Park, Hyunhye Kang, Jin Jung, Ae-Ran Choi, Raeseok Lee, Dong-Gun Lee, Eun-Jee Oh   +10 more
openaire   +3 more sources

Immunogenicity and efficacy of          heterologous ChAdOx1–BNT162b2 vaccination [PDF]

Nature, 2021
Abstract Following severe adverse reactions in patients vaccinated with the AstraZeneca ChadOx1 (Chad) vaccine, European health authorities have recommended that patients under the age of 55 who received one dose of Chad vaccine receive a second dose of Pfizer BNT162b2 (BNT) vaccine as a booster.
Bruno Pozzetto, Vincent Legros, Sophia Djebali, Véronique Barateau, Nicolas Guibert, Marine Villard, Loïc Peyrot, Omran Allatif, Jean-Baptiste Fassier, Amélie Massardier-Pilonchéry, Karen Brengel-Pesce, Melyssa Yaugel-Novoa, Solène Denolly, Bertrand Boson, Thomas Bourlet, Antonin Bal, Martine Valette, Thibault Andrieu, Bruno Lina, Kahina Saker, Christelle Compagnon, Bouchra Mokdad, Constance d’Aubarede, Virginie Pitiot, Vanessa Escuret, Florence Morfin, Mary-Anne Trabaud, Margaux Prieux, Valérie Dubois, Laurence Josset, Soizic Daniel, François-Loïc Cosset, Stéphane Paul, Thierry Defrance, Jacqueline Marvel, Thierry Walzer, Sophie Trouillet-Assant   +36 more
openaire   +5 more sources

Safety of the BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Setting

New England Journal of Medicine, 2021
Background Preapproval trials showed that messenger RNA (mRNA)–based vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) had a good safety profile, yet these trials were subject to size and patient-mix limitations. An evaluation
Noam Barda, Noa Dagan, Y. Ben-Shlomo, Eldad Kepten, Jacob G Waxman, Reut Ohana, M. Hernán, M. Lipsitch, I. Kohane, D. Netzer, Ben Y. Reis, R. Balicer   +11 more
semanticscholar   +1 more source

Protection of BNT162b2 Vaccine Booster against Covid-19 in Israel

New England Journal of Medicine, 2021
Background On July 30, 2021, the administration of a third (booster) dose of the BNT162b2 messenger RNA vaccine (Pfizer–BioNTech) was approved in Israel for persons who were 60 years of age or older and who had received a second dose of vaccine at least ...
Y. Bar-On, Y. Goldberg, Michael I. Mandel, O. Bodenheimer, L. Freedman, N. Kalkstein, B. Mizrahi, S. alroy-Preis, N. Ash, R. Milo, A. Huppert   +10 more
semanticscholar   +1 more source

SARS-CoV-2 Antibody Dynamics in Healthcare Workers after mRNA Vaccination

Vaccines, 2023
Since the emergence of SARS-CoV-2, maintaining healthcare worker (HCW) health and safety has been fundamental to responding to the global pandemic. Vaccination with mRNA-base vaccines targeting SARS-CoV-2 spike protein has emerged as a key strategy in ...
Kevin D. Dieckhaus, Min-Jung Kim, Jian-Bing Shen, Tina S. Liang, Michael J. Kleinberg, Kristen M. Siedlarz, David B. Banach, Mark L. Metersky, Rob P. Fuller, Eric M. Mortensen, Bruce T. Liang   +10 more
doaj   +1 more source

Could Prior COVID-19 Affect the Neutralizing Antibody after the Third BNT162b2 Booster Dose: A Longitudinal Study [PDF]

, 2023
Aşılama, devam eden COVID-19 salgını sırasında hastalığın yayılmasını önlemek için temel bir halk sağlığı önlemidir. Konakçının geliştirdiği immün yanıt veya aşının oluşturduğu immünolojik yanıtın devam etmesi, salgının gidişatını değiştirebileceği için ...
Buber, Suleyman, Demirci, Mehmet, Erdem, Mustafa Genco, Kocazeybek, Bekir Sami, Ünlü, Özge   +4 more
core   +2 more sources

Human immune and gut microbial parameters associated with inter-individual variations in COVID-19 mRNA vaccine-induced immunity [PDF]

, 2023
COVID-19 mRNA vaccines induce protective adaptive immunity against SARS-CoV-2 in most individuals, but there is wide variation in levels of vaccine-induced antibody and T-cell responses.
Collins Mary K., Hirota Masato, Ishikawa Hiroki, Kina Mitsuo, Kitano Hiroaki, Matthews Melissa M., Miyagi Masatake, Miyagi Mio, Mori Tomoari, Sakihara Eishin, Seto Yu, Taira Naoyuki, Tamai Miho, Tamai Osamu, Tamaki Kentaro, Toguchi Sakura, Toma Takeshi, Tomori Hiroaki, Wolf Matthias, Yamashiro Chiaki, Yoshida Makiko, Yukawa Sachie   +21 more
core   +1 more source

Évaluation de l'immunogénicité après vaccination COVID-19 hétérologue ChAdOx1-nCoV19/BNT162b2 et homologue BNT162b2/BNT162b2– Cohorte ANRS0001S COV-POPART

Médecine et Maladies Infectieuses Formation, 2022
INTRODUCTION: Le risque de thrombocytopénies thrombotiques immunitaires induites par le vaccin ChAdOx1-nCoV19 a conduit la France à recommander une seconde dose par un vaccin ARNm chez les personnes
Lachâtre, M., Loubet, P., Ninove, L., Gilbert, C., Merrien, D., Carcowski, C., Verdon, R., Maakaroun-Vermesse, Z., Launay, O., Wittkop, L.   +9 more
openaire   +1 more source

Safety, Immunogenicity, and Efficacy of the BNT162b2 Covid-19 Vaccine in Adolescents

New England Journal of Medicine, 2021
Background Until very recently, vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) had not been authorized for emergency use in persons younger than 16 years of age.
R. Frenck, N. Klein, N. Kitchin, A. Gurtman, J. Absalon, S. Lockhart, John L. Perez, E. Walter, S. Senders, R. Bailey, K. Swanson, Hua Ma, Xia Xu, K. Koury, W. Kalina, David Cooper, T. Jennings, Donald M Brandon, Stephen J. Thomas, Ö. Türeci, D. Tresnan, Susan H. Mather, P. Dormitzer, U. Şahin, K. Jansen, W. Gruber   +25 more
semanticscholar   +1 more source